•
Mar 31, 2024

AptarGroup Q1 2024 Earnings Report

AptarGroup's Q1 2024 results were driven by growth in proprietary drug delivery systems, increased injectables sales, and an improving picture for consumer dispensing technologies in North America.

Key Takeaways

AptarGroup reported a strong first quarter with a 6% increase in reported sales and a 5% increase in core sales. Net income increased by 52% to $83 million, with reported earnings per share up 50% to $1.23 and adjusted earnings per share up 31% to $1.26.

Reported sales grew 6% and core sales increased 5%.

Earnings per share increased 50% to $1.23, and adjusted earnings per share increased 31% to $1.26.

Net income increased 52% to $83 million, and adjusted EBITDA increased 16% to $179 million.

Pharma segment delivered reported sales growth of 14% and core sales growth of 13% due to continued demand for proprietary drug delivery systems.

Total Revenue
$915M
Previous year: $860M
+6.4%
EPS
$1.26
Previous year: $0.95
+32.6%
Total Core Sales Growth
5%
Previous year: 4%
+25.0%
Beauty + Home Core Sales Growth
-1%
Previous year: 9%
-111.1%
Pharma Core Sales Growth
13%
Previous year: 7%
+85.7%
Gross Profit
$268M
Previous year: $303M
-11.3%
Cash and Equivalents
$200M
Previous year: $127M
+57.6%
Free Cash Flow
$16.7M
Previous year: $20.5M
-18.6%
Total Assets
$4.44B
Previous year: $4.3B
+3.1%

AptarGroup

AptarGroup

AptarGroup Revenue by Segment

Forward Guidance

Aptar expects earnings per share for the second quarter of 2024 to be in the range of $1.30 to $1.38, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs. This guidance is based on an effective tax rate range of 22% to 24%.

Positive Outlook

  • Anticipate demand for proprietary drug delivery systems and elastomeric components for biologics to continue to grow in the second quarter.
  • Expect Pharma’s strong performance to continue throughout the year.
  • Expect demand to build for consumer dispensing technologies in the second quarter as destocking abates in North America.
  • Beauty will continue to focus on improving operational performance and ongoing cost management, including optimizing our footprint.
  • Closures will continue to focus on improving operational performance and ongoing cost management, including optimizing our footprint.

Revenue & Expenses

Visualization of income flow from segment revenue to net income